Physician profile
Catherine Yang Ding
NPI 1760749808
$756.27
in general payments reported to CMS, 2019-2025
13 companies · $333 in 2025
The $333 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $14.56 · 2021: $22.50 · 2022: $12.38 · 2024: $175 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $290 · Food and Beverage: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $289.64 |
| Food and Beverage | $218.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $194.98 | 2025 | Tremfya |
| Abbvie INC. | $130.57 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $118.17 | 2019-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $89.33 | 2019-2021 | |
| Inspire Medical Systems, INC. | $58.95 | 2024 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.45 | 2019 | |
| Incyte Corporation | $32.59 | 2025 | Opzelura |
| Lightforce Orthodontics, INC. | $21.29 | 2024 | |
| Galderma Laboratories, L.P. | $19.27 | 2019 | |
| Celgene Corporation | $15.96 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.67 | 2019 | |
| Merck Sharp & Dohme LLC | $14.73 | 2019 | |
| Organon LLC | $5.31 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Yang Ding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.